Planned DTC Rule Faces Legal, Leadership Uncertainties: FDLI Panel
FDA's anticipated proposal to restrict direct-to-consumer (DTC) prescription drug advertising could face significant statutory and First Amendment challenges, while changes in agency leadership raise questions about whether the administration's advertising enforcement campaign will maintain its momentum, attorneys said during a recent FDLI conference panel.
FDA plans to release a proposed rule in December that would require prescription drug advertisements on television, radio and similar broadcast media to include relevant risk, contraindication and safety information within the advertisements themselves, eliminating the longstanding option of directing consumers to outside sources for that information. The agency ties the planned rulemaking to a 9/2025 presidential memorandum (see earlier story) directing HHS and FDA to increase transparency and accuracy in prescription drug advertising by requiring more information about drug risks, to the extent permitted by law.
The proposal, listed in HHS' 2026 Unified Agenda, would amend 21 CFR 202.1 by removing the "adequate provision" pathway that currently allows broadcast advertisements to satisfy the statutory "brief summary" requirement by referring consumers to FDA-approved labeling through toll-free telephone numbers, print materials or websites. According to the Unified Agenda entry, FDA argues that the regulatory framework established following its 1999 guidance created a "loophole" allowing important safety information to be placed outside the advertisement rather than presented directly to consumers.
FDLI panelists said the scope of FDA's proposal remains uncertain, including whether the agency will seek to eliminate the adequate provision mechanism entirely or adopt narrower restrictions. One attorney said eliminating the provision could make conventional television and radio drug advertising substantially more difficult, given the volume of risk information that companies might otherwise be required to communicate within short advertisements. The changes could also disproportionately affect smaller pharmaceutical companies that lack the resources to accommodate substantially expanded disclosures or develop alternative promotional strategies.
Attorneys predicted that an aggressive proposal would draw extensive public comments and potentially face challenges under the Administrative Procedure Act, FDA's statutory authority and the First Amendment. Arnold & Porter senior associate Jonathan Trinh said some pharmaceutical companies are already preparing comments on the anticipated proposal, even though FDA has not published a draft rule. He said companies are also considering alternative commercial strategies, including directing more communications toward healthcare professionals rather than consumers.
The panel also discussed a Public Citizen petition seeking a complete prohibition on DTC prescription drug advertising, a more sweeping approach than the regulatory changes FDA has publicly contemplated. The petition cites peer-reviewed evidence suggesting that DTC advertisements misleadingly present the benefits and risks of medications and use favorable, selective imagery to influence consumers' emotions.
Leadership Changes Could Alter Enforcement Priorities
The uncertainty surrounding the rulemaking comes as attorneys question whether FDA will maintain the intensity of its advertising enforcement initiative launched in 9/2025. Trinh noted that the number of enforcement letters has declined substantially since March, raising questions about whether the campaign will continue at its earlier pace. He also pointed to the prospect of new FDA leadership, observing that DTC advertising had not emerged as a significant issue during commissioner nominee Heidi Overton's recent Senate confirmation hearing.
Melissa Mendoza, a partner at Hogan Lovells and former director of CBER's Office of Compliance and Biologics Quality, said changes in FDA’s leadership could substantially affect enforcement priorities. However, she emphasized that the administration's original DTC advertising initiative was driven largely by HHS leadership, suggesting that the department could remain the principal force behind regulatory changes regardless of the incoming commissioner's priorities.
Mendoza said it remains unclear how HHS currently views the proposed rule after more than a year of considering the policy and its potential legal implications. "What's the mentality and what's the mindset at HHS currently after over a year of maybe thinking about the proposed rule, hopefully working closely with agency career staff to understand how the agency got to this particular point, and better understanding the landscape and the First Amendment concerns," she said. "I think there is a lot of uncertainty there."
The panelists generally expected FDA to continue issuing advertising enforcement letters, although they questioned whether another large-scale enforcement campaign similar to 9/2025 would occur.
They also suggested that any final restrictions on broadcast advertising could remain tied up in litigation for a considerable period, leaving pharmaceutical companies facing uncertainty over both the eventual regulatory requirements and the agency's enforcement priorities.